Effects of @entity3624 oxidase inhibitors on @entity65 in @entity1 with XXXX : a cohort study.

@entity1 @entity64 @entity712 @entity583 @entity3624 @entity20082 @entity5052 @entity210 @entity208 @entity65 @entity414
BACKGROUND: @entity5052 and @entity210 are associated with an increased risk of @entity65 ( @entity65 ). It is unknown whether treating @entity5052 with @entity3624 oxidase inhibitors (XOIs), including @entity208 and @entity20082 , modifies @entity65 . METHODS: We used US insurance claims data to conduct a cohort study among @entity210 @entity1 , comparing XOI initiators with non-users with @entity5052 defined as serum @entity414 level >= 6.8 mg/dL. We calculated incidence rates of a composite nonfatal cardiovascular outcome that included @entity583 , coronary revascularization, @entity64 , and @entity712 . Propensity score (PS)-matched Cox proportional hazards regression compared the risk of composite cardiovascular endpoint in XOI initiators vs those with untreated @entity5052 , controlling for baseline confounders. In a subgroup of @entity1 with @entity414 levels available, PS-matched Cox regression further adjusted for baseline @entity414 levels. RESULTS: There were 24,108 PS-matched pairs with a mean age of 51 years and 88% male. The incidence rate per 1000 @entity1 -years for composite @entity65 was 24.1 (95% confidence interval [CI] 22.6-26.0) in XOI initiators and 21.4 (95% CI, 19.8-23.2) in the untreated @entity5052 group. The PS-matched hazard ratio for composite @entity65 was 1.16 (95% CI, 0.99-1.34) in XOI initiators vs those with untreated @entity5052 . In subgroup analyses, the PS-matched hazard ratio for composite @entity65 adjusted for serum @entity414 levels was 1.10 (95% CI, 0.74-1.64) among XOI initiators. CONCLUSIONS: Among @entity1 with @entity210 , initiation of XOI was not associated with an increased or decreased cardiovascular risk compared with those with untreated @entity5052 . Subgroup analyses adjusting for baseline @entity414 levels also showed no association between XOI and cardiovascular risk.
